CD34 and neoplasm: The anti-tumor efficacy of 22.0405.aF was assessed in human CD34+ hematopoietic stem cell (huHSC) humanized NCG-hIL15 mice inoculated subcutaneously with JeKo-1 cells on the right flank/shoulder.